Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"company":"CureVac","sponsor":"Tesla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"company":"CureVac","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Nets EU Funding to Ramp up Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"company":"BioNTech","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$139.0 million","newsHeadline":"Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"company":"CureVac","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Proposed Initial Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"company":"CureVac","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","amount":"$297.8 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"company":"IDT Biologika GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Germany Approves Third Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"IDT Biologika GmbH"},{"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evotec Starts Clinical Development of Chikungunya Antibody Together with NIAID and Leading Academic Research Organisation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Evotec"},{"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"}]

CureVac

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Details:

CV0501 is CureVac’s first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK. It is based on CureVac’s advanced second-generation mRNA backbone.

Lead Product(s): CV0501

Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2022

ASK
US

Upload
your Pipeline Activity

Evotec

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Evotec Starts Clinical Development of Chikungunya Antibody Together with NIAID and Leading Academic Research Organisation

Details:

EVT894 is a fully human monoclonal antibody that targets a viral protein and has shown potent neutralising activity in in vitro and in vivo models. First Dose of Evt894, a Monoclonal Antibody Against Chikungunya Virus Administered to A Healthy Participant IN A Phase I Study.

Lead Product(s): EVT894

Therapeutic Area: Infections and Infectious Diseases Product Name: SAR440894

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2021

ASK
US

Upload
your Pipeline Activity

IDT Biologika GmbH

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Germany Approves Third Trial of COVID-19 Vaccine Candidate

Details:

The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.

Lead Product(s): MVA-SARS-2-S vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 02, 2020

ASK
US

Upload
your Pipeline Activity

CureVac

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research

Details:

Funding will support the development of its COVID-19 vaccine candidate. In July 2020, CureVac had applied to a grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2.

Lead Product(s): mRNA based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: German Federal Ministry of Education and Research

Deal Size: $297.8 million Upfront Cash: Undisclosed

Deal Type: Funding September 04, 2020

ASK
US

Upload
your Pipeline Activity

CureVac

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CureVac Announces Proposed Initial Public Offering of Common Shares

Details:

The net proceeds will support Company’s mRNA vaccine program against SARS-CoV-2 through the completion of Phase 3; will be used to fund the expansion of the Company’s short term manufacturing capabilities; to advance the Company’s lead oncology program, CV8102.

Lead Product(s): mRNA based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: BofA Securities

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering August 10, 2020

ASK
US

Upload
your Pipeline Activity

CureVac

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CureVac Nets EU Funding to Ramp up Vaccine Production

Details:

The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany.

Lead Product(s): mRNA based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: European Investment Bank

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 06, 2020

ASK
US

Upload
your Pipeline Activity

CureVac

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says

Details:

CureVac has reportedly snared a big partner to help build its game-changing RNA "printers" that could turn global interest back in its favor.

Lead Product(s): mRNA based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Tesla

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 02, 2020

ASK
US

Upload
your Pipeline Activity

BioNTech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms

Details:

BioNTech is expected to post data from its Phase I/II trial virtually any day now, as analysts expect some hard numbers on immunogenicity and safety for BNT162 in the June/July time frame.

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Temasek

Deal Size: $250.0 million Upfront Cash: $139.0 million

Deal Type: Funding June 29, 2020

ASK
US

Upload
your Pipeline Activity

CureVac

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

Details:

German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for CureVac's vaccine program to prevent SARS-CoV-2 infection.

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY